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Abstract
Purpose Due to an increased human life expectancy, the need to replace arthritic or dysfunctional joints by prosthetics is higher
than ever before. Prosthetic joints are unfortunately inherently susceptible to bacterial infection accompanied by biofilm forma-
tion. Accurate and rapid diagnosis is vital to increase therapeutic success. Yet, established diagnostic modalities cannot directly
detect bacterial biofilms on prostheses. Therefore, the present study was aimed at investigating whether arthroscopic optical
imaging can accurately detect bacterial biofilms on prosthetic joints.
Methods Here, we applied a conjugate of the antibiotic vancomycin and the near-infrared fluorophore IRDye800CW, in short
vanco-800CW, in combination with arthroscopic optical imaging to target and visualize biofilms on infected prostheses.
Results We show in a human post-mortem prosthetic knee infection model that a staphylococcal biofilm is accurately detected in
real time and distinguished from sterile sections in high resolution. In addition, we demonstrate that biofilms associated with the
clinically most relevant bacterial species can be detected using vanco-800CW.
Conclusion The presented image-guided arthroscopic approach provides direct visual diagnostic information and facilitates
immediate appropriate treatment selection.
Keywords Infection imaging . Prosthetic joint . Biofilm . Optical tracer . Fluorescence
Introduction
Human life expectancy is presently higher than ever before.
The need for biomaterials to replace arthritic or dysfunctional
body parts by prosthetics has, therefore, never been greater
[1]. Total joint replacement with a prosthesis is nowadays
the most performed substitute, which usually contributes to
an enhanced quality of life. Approximately 2% of the patients,
however, experience device failure in the form of a bacterial
infection of the prosthesis and adjacent tissue [2]. These pros-
thetic joint infections (PJIs) are dreaded complications. They
are difficult to diagnose, can manifest at any time after
arthroplasty, and usually require multiple surgeries and a
prolonged course of antibiotic treatment [3–5]. The economic
impact of PJIs is accordingly significant with yearly estimated
treatment costs exceeding $1.5 billion in the USA alone [2].
Implanted biomaterials are highly susceptible to infection
due to biofilm formation on the prosthetic surface. A bacterial
biofilm is a sessile community of bacteria surrounded by a
matrix of extracellular polymeric substances (EPS) [6]. The
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matrix, which is produced by the bacteria, acts as a structural
network. It captures and disseminates nutrients and functions
as a barrier for the host immune system and antibiotics. These
properties make the eradication of bacterial biofilms challeng-
ing. Moreover, the bacterial tolerance to therapeutic interven-
tions increases as the biofilm matures [7]. This calls for inno-
vative diagnostic tools that allow their early detection.
Established diagnostic modalities for PJIs, such as blood tests,
analysis of synovial fluid, culturing, biopsies, and imaging all
have their pros and cons in detecting infection, but no test is
100% accurate for PJI [8–10]. As a result, the diagnosis often
remains unclear, whereas the proper therapeutic approach is un-
certain. One factor that consistently plays a role in biomaterial-
associated infection, however, is bacterial biofilm formation. Up
to date, there are no diagnostic procedures capable of in vivo
detection of bacterial biofilm on a (total) joint prosthesis.
Targeted fluorescence (i.e., optical) imaging (TFLI) has
great potential for the in vivo detection of bacterial infections
[11]. It relies on the administration of a tracer that consists of an
exogenous fluorophore conjugated to a bacteria-targeting mo-
lecular probe. After administration of the tracer, a sensitive
optical camera readily detects the fluorescence emission at the
infection site and converts this into an image on a screen. This
allows for high-resolution, low-cost imaging in real time. A
promising tracer is vanco-800CW, which is a conjugate of the
antibiotic vancomycin and the near-infrared (NIR) fluorophore
IRDye800CW (Fig. 1) [12]. Vanco-800CW is particularly suit-
able for the detection of PJIs as vancomycin targets the cell wall
of Gram-positive (GP) bacteria. Bacteria belonging to this class
are the most frequently encountered causative agents of
biomaterial-associated infections [8]. Previously, our team has
demonstrated that this tracer can be successfully applied to
detect a range of planktonic GP bacteria, to detect staphylococ-
cal infections in mice, and to image an infected implant through
several millimeters of human skin [12].
The present proof-of-principle study was aimed at evaluat-
ing the possible use of vanco-800CW for detection of PJIs. A
human post-mortem prosthetic knee infection model was used
to assess the clinical feasibility of detecting bacterial biofilms
through TFLI. An arthroscopic approach was chosen for im-
aging the bacterial biofilms directly intra-articularly on the
implanted prosthesis. In addition to the arthroscopy, an
in vitro experiment was performed to verify that vanco-
800CW is a suitable tracer for the detection and imaging of
a representative panel of clinical PJI-causing bacterial isolates.
Materials and methods
Human post-mortem experiments
The post-mortem experiments were performed in duplicate,
using the legs of two human cadavers, where each leg was
used only once. Both individuals had provided written in-
formed consent for the post-mortem use of their bodies for
scientific research. All post-mortem experiments were con-
ducted in accordance with the applicable law (“Wet op de
Lijkbezorging,” Art 18, lid 1 and 19, BWBR0005009) and
institutional guidelines of the UMCG.
Fig. 1 Schematic representation of vanco-800CW and its binding to the
bacterial cell wall. The fluorescent tracer vanco-800CW is a conjugate of
the antibiotic vancomycin and the near-infrared fluorophore
IRDye800CW. It binds to the D-Ala-d-Ala moieties of N-acetylmuramic
acid and N-acetylglucosamine peptides in the cell wall of Gram-positive
bacteria [12]
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Biofilm formation on the lateral part of a knee prosthesis
Before implantation in human cadaver knee joints, cobalt-
chrome knee prostheses (size 5 triathlon femoral component;
Stryker®, USA)were coated with a biofilm of Staphylococcus
epidermidis. To this end, the S. epidermidis American Type
Culture Collection (ATCC) strain 35984 was cultured over-
night in 10 mL Tryptic Soy Broth (TSB) at 37 °C. One milli-
liter of the S. epidermidis culture with an optical density at
600 nm (OD600) of 0.1 was transferred to a sterile container
with 199 mL TSB, 5% glucose, and 4% sodium chloride
(NaCl). Next, a knee prosthesis was incubated in the suspen-
sion with the lateral segment submerged. Accordingly, in this
standing culture system, biofilm formation would only occur
at the submerged lateral prosthetic region. This allowed for
distinction during the arthroscopy between parts with biofilm
(lateral side) or without biofilm (medial side). The prosthesis
was biofilm-coated in 4 days at 37 °C. During this period,
medium was manually refreshed once per day by removing
199 mL of suspension and replacing it by 199 mL of fresh
TSB with 5% glucose and 4% NaCl.
Formation of a biofilm matrix of EPS on the knee prosthe-
sis was verified by growing the biofilms in the presence of
0.2 mg/mL or 20 mg/mL Congo Red stain (Sigma-Aldrich,
Germany) for 4 days at 37 °C as described above [13].
Subsequently, the prosthesis was washed twice with
phosphate-buffered saline (PBS) and incubated for 30 min
with Congo Red (0.004 mg/mL). Lastly, the prosthesis was
washed twice with PBS to remove any unbound stain. Images
of the stained biofilm on the prosthesis were recorded with a
photographic camera.
Total knee arthroplasty
The human cadaver knee joint was disinfected and draped. A
longitudinal midline incision anterior of the knee joint was
made, the joint was opened in a medial parapatellar fashion
to gain access to the knee, and the patella was everted laterally.
Subsequently, the knee joint was placed in 90° of flexion. The
distal femoral bone cuts were performed using an oscillating
saw to allow accurate placement of the femoral component of
the prosthesis. A biofilm-coated prosthesis (as described
above) was implanted on the distal femur (Fig. 2). Suturing
of the soft tissues was performed in a double layer technique
to allow for watertight closure (Ethilon 3-0, Ethicon
Somerville, NJ, USA).
Imaging procedures and incubation with vanco-800CW
The knee was placed in 90° of flexion. An intra-articular por-
tal was made by a small incision of 1 cm lateral to the lateral
border of the patella tendon in the soft spot just distal to the
pole of the patella. An arthroscope (Arthrex, Naples, FL,
USA) connected to a saline irrigation pressure pump was
placed inside the knee joint cavity. Physiological saline solu-
tion (“saline”) was pumped into the joint for distention. The
prosthesis was then imaged with a white-light and NIR light
camera (SurgVision Explorer Custom, Netherlands) with a
fluorescence fiber attached to it (Schoelly Fiberoptic GmbH,
Germany) as a control prior to the injection of vanco-800CW.
The saline was sucked out of the knee with the irrigation
system after this first round of imaging.
After imaging, the knee was placed in full extension and
20 mL of vanco-800CW dissolved in saline (0.07 nmol/mL,
LI-COR Biosciences, NE, USA) was injected into the knee
joint cavity (Fig. 3-1). The joint was then manually flexed
and extended five times to ensure an even dispersion of the
tracer. After a 15-min incubation period in extension, the knee
joint cavity was thoroughly flushed with the arthroscope irriga-
tion systemwith 2 L saline to remove all unbound tracer as well
as any planktonic bacteria that could potentially be present
(Fig. 3-2). Thereafter, the imaging procedure was repeated
(Fig. 3-3).
TFLI of biofilms of clinical bacterial isolates using
vanco-800CW
A representative panel of commonly encountered PJI-causing
bacterial pathogens, both GP and Gram-negative (GN), was
collected from the diagnostic laboratory of the UMCG. All
clinical isolates were retrieved from sonicated infected
Fig. 2 Image from the anterior side of the biofilm-coated prosthesis after
implantation in the left knee of a human cadaver. The lateral part of the
prosthesis was biofilm-coated with S. epidermidis, whereas the medial
part was essentially sterile
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biomaterials from patients. Ethical approval for the collection
of patient samples was obtained from the medical ethical com-
mittee at the UMCG (METC 2017/526). Biofilms of these
strains, plus a biofilm of the S. epidermidis ATCC 35984
strain (used in the post-mortem experiments), were formed
on cobalt-chrome discs (diameter 2.5 cm) in 4 days following
the same inoculation and standing culture protocol as de-
scribed for the post-mortem experiments above. These bioma-
terials, plus one sterile control containing no biofilm, were
incubated with vanco-800CW (0.07 nmol/mL) and washed
twice with PBS. White-light and NIR images were recorded
using a fluorescence camera (SurgVision Explorer Air,
Netherlands). The formation of EPS in the S. epidermidis bio-
film was assessed by staining with Congo Red as described
above [13]. The stained and imaged biomaterials were soni-
cated after which serial dilutions of the sonication-fluid were
made. Samples were plated on blood agar plates (5% sheep
blood, Mediaproducts B.V., the Netherlands), and numbers of
colony-forming units (CFUs) were determined. The experi-
ment was performed in duplicate.
Fluorescence microscopy of S. epidermidis biofilms
S. epidermidis ATCC 38984 was grown overnight at 37 °C in
TSB using a shaking incubator. Subsequently, the bacteria
were diluted in TSB supplemented with 5% glucose and 4%
NaCl to a final OD600 of 0.1 and incubated in a 12-well
microtiter plate containing 18 mm chemically resistant boro-
silicate glass coverslips for microscopy (Paul Marienfeld
GmbH, Germany). After 48 h of incubation, the coverslips
were incubated for 15 min with vancomycin at 0.5, 1, 2, 4,
or 8 mg/L final concentration or without vancomycin.
Subsequently, the coverslips were washed once with PBS,
incubated with 0.07 nmol/mL of vancomycin-BODIPY™
FL (vanco-BODIPY) for 15 min (Thermo Fisher Scientific,
USA), washed once with PBS to remove any unbound tracer,
and fixed with 4% paraformaldehyde. Finally, the coverslips
Fig. 3 Schematic overview of arthroscopic biofilm imaging using vanco-
800CW. (1) Vanco-800CW is injected intra-articularly, where it binds to
the cell wall of biofilm-resident Gram-positive bacteria. (2) By
arthroscopically flushing the joint with physiological saline solution, un-
bound vanco-800CW is removed. As a consequence, this tracer is solely
retained in areas where it is bound to Gram-positive bacteria in the bio-
film. (3) The joint is arthroscopically imaged in the near-infrared range.
Fluorescence of vanco-800CW bound to bacteria in the biofilm is visu-
alized on a screen. A video showing the procedure is provided as supple-
mental Movie 1
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were mounted on microscopy slides. Image acquisition was
performed with a Leica TCS SP8X microscope.
Data analysis
Fluorescence images of the post-mortem experiments and the
biofilm experiments with clinical bacterial isolates were ana-
lyzed using the ImageJ software package (National Institutes
of Health, MD, USA). The detection limit for the fluorescence
signal was set at the lowest value at which biofilm signals
were visually easily discernible from the negative control sig-
nal at biofilm-free sites. For the fluorescence assay, regions of
interest (ROIs) were drawn around fluorescent biofilm–coated
regions on the biomaterials after which the software quantified
the fluorescence signal. The background fluorescence was
quantified by drawing a ROI off-target in a background area
of the same image. To determine the target-to-background
(T/B) ratio, ROIs were divided by the background fluores-
cence. Graphs were plotted using GraphPad Prism 8.1.1
(GraphPad Software, CA, USA). The fluorescence microsco-
py images recorded to assess competition of the antibiotic
vancomycin with vanco-BODIPY for binding to
S. epidermidis ATCC 38984 were processed using Imaris
9.5.0 software (Oxford Instruments, UK).
Results
Human post-mortem experiment
To assess the formation of genuine S. epidermidis biofilms on
cobalt-chrome biomaterials, we investigated the presence of
EPS by staining the bacteria that had adhered to discs and
knee prostheses with Congo Red [13]. This showed that after
4 days of culturing, S. epidermidis had indeed formed EPS-
containing biofilms on these biomaterials (Fig. 4).
The clinical feasibility of detecting bacterial biofilms
through TFLI was evaluated by total knee arthroplasty with
prostheses coated with (unstained) S. epidermidis biofilms
on the lateral part and subsequent arthroscopy. Arthroscopic
images captured by the white-light camera revealed the spa-
tial distribution of the S. epidermidis biofilm on the lateral
part of the prosthesis (Fig. 5-C, red dotted line). At the un-
coated medial part of the prosthesis, no biofilm was visible
(Fig. 5-A). Prior to the administration of vanco-800CW, no
NIR fluorescence signalwasdetectable at both the lateral and
the medial side of the prosthesis compared with the back-
ground. Upon incubation with vanco-800CW and subse-
quentwashingwith saline, the recordedNIR images revealed
a strong fluorescence signal emitted from the biofilm-coated
lateral part of the prosthesis (Fig. 5-D), whereas the uncoated
medial part showed no fluorescence signal, comparable to
the background (Fig. 5-B). Co-localization revealed a high
degree of overlap between the white-light camera image and
the fluorescence image (Fig. 5-C, D). Close-up images of the
biofilms captured with the white-light camera and the NIR
fluorescence camera were subsequently compared. Minor
interruptions in the biofilm of only several millimeters wide
(Fig. 6-A) were detectable with the white-light camera.
These shapes could easily be recognized by the NIR fluores-
cence camera (Fig. 6-B), providing proof-of-principle that
vanco-800CW and arthroscopic optical imaging can be ap-
plied for high-resolution visualization of bacterial biofilms
on infected prostheses.
TFLI to detect biofilms of clinical bacterial isolates
using vanco-800CW
A representative panel of 14 clinical bacterial isolates was
collected and used to grow in vitro biofilms on cobalt-
chrome discs. The panel consisted of Staphylococcus aureus
(2 isolates, GP), S. epidermidis (2 isolates, GP),
Staphylococcus lugdunensis (2 isolates, GP), Staphylococcus
caprae (2 isolates, GP), Enterococcus faecalis (2 isolates,
GP), Escherichia coli (2 isolates, GN), and Pseudomonas
aeruginosa (2 isolates, GN). In addition, biofilms of the
S. epidermidis ATCC 35984 strain were grown on duplicate
discs for control. Results of the subsequent biofilm imaging
are shown in Fig. 7 (note that per strain only one image is
shown). The biofilms of all GP bacterial isolates emitted a
strong fluorescence signal (well above 1.0 × 104 fluorescence
units). In contrast, the GN bacterial isolates emitted a substan-
tially lower fluorescence signal (0.5–1.0 × 103 fluorescence
units), as was to be expected because vancomycin particularly
targets GP bacteria. The fluorescence signal detectable for the
sterile controls was comparable to the background (< 0.5 ×
103 fluorescence units). After sonication and plating of the
sonicates, the CFUs measured for the GP isolates (median
1.9 × 109) were comparable to the CFUs measured for the
GN strains (median 3.5 × 108; see Supplementary Table 1
for the CFU counts and fluorescence measurements per ROI
per species). Calculated average T/B ratios per species are
shown in Fig. 8. All the GP strains showed a substantially
higher T/B ratio (range 14.2–56.5, median 31.8) than the
GN strains (range 3.2–3.5, median 3.4). The T/B ratios for
the sterile biomaterials were 1, meaning that the sterile control
presented the same fluorescence intensity as the unstained
background.
Competitive inhibition of S. epidermidis biofilm
staining with fluorescent vancomycin by unlabelled
vancomycin
To ascertain that the observed staining of GP bacterial
biofilms by the fluorescently labelled vancomycin was vanco-
mycin-specific, we performed a blocking experiment with
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unlabelled vancomycin. To this end, S. epidermidis biofilms
grown on microscopy coverslips were treated with unlabelled
vancomycin prior to the incubation with fluorescently labelled
vancomycin and fluorescence microscopy. In this case, we
used vanco-BODIPY instead of vanco-800CW, as vanco-
BODIPY was more suitable for high-resolution fluorescence
microscopy of biofilms in our setup. The results of the fluo-
rescence microscopy analyses are shown in Fig. 9. Indeed,
pre-treatment of the biofilms with vancomycin at concentra-
tions higher than 2 mg/L resulted in a gradual decrease of
biofilm staining by vanco-BODIPY. This shows that the ob-
served labelling with fluorescent vancomycin derivatives is
vancomycin-specific.
Discussion
In this proof-of-principle study, we show that arthroscopic de-
tection and real-time imaging of bacterial biofilms on a human
knee prosthesis are feasible with vanco-800CW. In addition,
we demonstrate that this tracer is highly effective in tracking
biofilms formed by representative clinical GP bacterial isolates.
As current diagnostic modalities for the detection of PJIs often
yield inconclusive results, successful treatment can be ham-
pered and lead to an increased patient- and healthcare burden.
Therefore, the development of fast and accurate novel bacteria-
targeting diagnostic modalities is desirable. The potential ad-
vantages of arthroscopic TFLI in comparison with present
Fig. 4 S. epidermidis biofilms stained with Congo Red. S. epidermidis
biofilms were grown in 4 days on cobalt-chrome discs in the presence of
20 mg/mL (A) or 0.2 mg/mL (B) Congo Red. The S. epidermidis biofilm
on the cobalt-chrome knee prosthesis, formed after 4 days of culturing,
was stained for 30 min with 0.004 mg/mL Congo Red (C). Red staining
of the biofilms marks the presence of extracellular polymeric substances
(EPS)
Fig. 5 Fluorescence arthroscopic imaging of bacterial biofilms in a
human post-mortem knee implant model. The green stain represents a
S. epidermidis biofilm, applied in vitro prior to arthroplasty. Images were
obtained after 15 min incubation with vanco-800CW and subsequent
washing with saline. (A) White-light image (WLI) of the uncoated
biofilm-free part of the prosthesis. (B) Corresponding near-infrared fluo-
rescence image (FLI) of the uncoated part of the prosthesis. The bar on the
right marks the corresponding fluorescence signal intensity. The bright
spot in the upper image is caused by white-light reflection on the implant.
(C) WLI of the biofilm-coated part of the prosthesis. The biofilm-coated
areas are highlighted by the red dotted lines. (D) Corresponding near-
infrared FLI of the biofilm-coated part of the prosthesis. The bar on the
right marks the corresponding fluorescence signal intensity. Settings for
fluorescence measurements: exposure 200 ms and gain 300
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diagnostic modalities for PJIs are considerable. The presently
shown ability of TFLI to detect and image bacterial biofilms in
situ on a prosthesis, both in high-resolution and in real time, are
aspects that mark this technology’s exceptional potential for
clinical implementation.
Especially in oncological research, pioneering clinical
studies have demonstrated the benefits of TFLI-guided detec-
tion of cancer, surveillance biopsies, and surgical resection
[15, 16]. To date, infection imaging with TFLI has never been
done in patients but has proven extremely promising in vitro
and in vivo [11]. Due to recent (technical) advances
concerning fluorophores, targeting molecules, and optical
camera systems, the first-in-man studies exploiting TFLI in
infection imaging are expected within the next few years ac-
cording to Mills et al. [17]. Moreover, fluorescently labelled
antimicrobial peptides and antibiotics, such as vanco-800CW,
are likely to be the first tracers used in clinical practice. Before
clinical introduction, vanco-800CW awaits toxicity testing
and good manufacturing practices to ensure its safety. In this
respect, it is noteworthy that vancomycin and the
IRDye800CW have, as separate molecules, already been ap-
proved for clinical implementation. Importantly, as imaging is
performed with an extremely low dose of vanco-800CW
(0.07 nmol/mL), which is ~ 20- to 40-fold below the minimal
inhibitory concentration (MIC) of vancomycin for staphylo-
cocci (https://eucast.org/clinical_breakpoints/), the possible
side effects associated with vancomycin and a rapid
selection for antimicrobial resistance are unlikely [11].
Consistent with this view, we observed thus far no effects of
the tracer at these concentrations on culture results. We
consider it therefore also unlikely that the described imaging
approach could interfere with subsequent routine culturing.
Furthermore, as vanco-800CW fluoresces in the NIR range,
interfering tissue autofluorescence is minimal [18]. Indeed, in
our human cadaver model, there was relatively little autoflu-
orescence detectable. This has also been shown in live animal
models [12] and oncologic TLFI studies where IRDye800CW
was used [15].
Due to the characteristics of fluorophores and camera sys-
tems, TFLI is currently mainly suitable for imaging of super-
ficial targets and intra-operative or endoscopic approaches.
The NIR imaging system used in the present post-mortem
experiment was, for example, designed for wide-field endos-
copy and clinically implemented in the Gastroenterology and
Hepatology departments of our hospital [19]. Our present
study is the first in its kind that combines TFLI with arthros-
copy. Importantly, by imaging the prosthesis intra-articular at
the prosthetic surface, less fluorescence signal is lost com-
pared with non-invasive imaging outside the knee joint.
Accordingly, increased sensitivity and resolution in the detec-
tion of infection can be achieved [20]. This is underpinned by
the observation that minor interruptions in the biofilm could
arthroscopically be visualized with the fluorescence camera at
submillimeter resolution (Fig. 6) during the post-mortem
experiments.
In the clinic, around 60–70% of PJIs are caused by
S. aureus, coagulase-negative staphylococci, streptococci,
and enterococci, which are all GP bacteria, while less
than 10% are caused by aerobic GN bacteria [8].
Judged by these percentages, vanco-800CW is suitable
for the detection of PJIs in the majority of cases. This
view is underscored by the finding that biomaterials
coated with GP bacterial biofilms could, after treatment
with vanco-800CW, all be easily discriminated from the
Fig. 6 Close-up arthroscopic image of a S. epidermidis biofilm in a
human post-mortem prosthetic knee model. Images were obtained after
15 min incubation with vanco-800CW and subsequent washing with
saline (A) White-light image (WLI) of the biofilm. There is a 3-mm wide
interruption in the biofilm-coated part where biofilm is missing, which is
highlighted by the red line. The bright spot above the highlighted area is
caused by white-light reflection on the implant. (B) Near-infrared fluo-
rescence image (FLI) of the biofilm. The bar on the right marks the
corresponding fluorescence signal intensity. Note the absence of fluores-
cence signal at the biofilm-free part of the prosthesis, which correlates
with the zone highlighted by the red line in panel A. Settings for fluores-
cence measurements: exposure 800 ms and gain 300
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tested GN bacteria and controls. The measured T/B ratios
further showed that the GP bacterial strains with bound
vanco-800CW emit fluorescence to a much higher level
than the GN strains compared with the background. This
finding is consistent with the notion that vanco-800CW
is preferentially bound by GP bacteria [11]. The binding
specificity of the fluorescently labelled vancomycin was
further reinforced by the observed competitive inhibition
of biofilm labelling through the pre-treatment of an
S. epidermidis biofilm with non-labelled vancomycin at
increasing concentrations. Observing that low amounts of
vanco-800CW were also bound by the GN bacterial
biofilms was surprising, but this finding can possibly
be explained by the fact that peptidoglycan, the target
for vanco-800CW, may not be fully covered in all in-
stances by the GN bacterial outer membranes. This ap-
plies, for example, to dead bacteria. Whether this repre-
sents sufficient vanco-800CW accumulation to detect GN
bacterial biofilms in a clinical context is yet to be ex-
plored. However, based on our findings, we anticipate
that arthroscopic TFLI with vanco-800CW will have a
much lower sensitivity for the detection of GN bacteria
involved in PJI than for GP bacteria. Importantly, this
potential limitation of the presently explored arthroscopic
imaging approach can be overcome by multispectral ar-
throscopic imaging with multiple simultaneously applied
tracers that target different microbial species, including
GN bacteria. Considering that empirical antibiotic thera-
py may be less frequently needed, the direct diagnostic
approach based on arthroscopic optical imaging is likely
to result in better therapeutic regimens while, at the same
time, less antimicrobial resistance may be elicited [21].
Some other limitations of this study need to be considered.
Firstly, to reliably assess whether a prosthesis is infected, it
also has to be scanned at spots were imaging is difficult. This
mostly concerns the edges of the prosthesis and the prosthesis-
bone interface. The imaging fiber used in the present experi-
ment was not ideal for monitoring these spots due to a restrict-
ed maneuverability of the tip. This will also apply to the im-
aging of other joints, for example, hip prostheses, where ar-
throscopy is even more challenging. These practical
Fig. 7 White-light images (WLI) and fluorescence images (FLI) of bac-
terial biofilms on cobalt-chrome biomaterials after treatment with vanco-
800CW. The bacterial isolates were derived by sonication of infected
prostheses with the exception of the S. epidermidis ATCC 35984 strain,
which was also used in the post-mortem experiments. Images were ob-
tained after 15 min incubation with vanco-800CW and subsequent wash-
ing with PBS. Of note, the S. epidermidis ATCC 35984 strain is known
for its ability to rapidly form thick biofilms [14]. Consequently, the
biofilms formed by the ATCC 35984 strain were thicker and bound more
vanco-800CW than those formed by the clinical isolates. The bar on the
right marks the correspondence of color in the FLI to fluorescence signal
intensity. Settings for fluorescence measurements: exposure 25 ms and
gain 300
Fig. 8 Average target-to-background (T/B) ratios for bacterial biofilms
stained with vanco-800CW. Bacterial strains used to grow duplicate
biofilms on cobalt-chrome biomaterials were derived by sonication of
infected prostheses as described for Fig. 7. Upon staining of the biofilms
with vanco-800CW, the average T/B ratios were determined for each
strain. The Gram-positive bacterial strains included clinical isolates of
S. aureus, S. epidermidis, S. lugdunensis, S. caprae, and E. faecalis, as
well as the S. epidermidis ATCC 35984 strain. The Gram-negative bac-
terial strains included clinical E. coli and P. aeruginosa isolates.
Fluorescence signals were quantified with ImageJ software
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restrictions still need to be addressed before clinical imple-
mentation can be considered. Secondly, careful selection of
patients who might benefit from arthroscopic TFLI is impor-
tant, as arthroscopy is a minimally invasive procedure and
Fig. 9 Competitive inhibition of
S. epidermidis biofilm staining
with fluorescent vancomycin by
increasing concentrations of
unlabelled vancomycin.
S. epidermidis biofilms were
grown on microscopy coverslips.
The biofilms were incubated for
15 min with different
concentrations of unlabelled
vancomycin (up to 8 mg/L;
shown on the left), or without
vancomycin. After washing with
PBS, the biofilms were stained
with vanco-BODIPY for 15 min.
White-light (WLI) and fluores-
cence images (FLI) were recorded
with a Leica TCS SP8X micro-
scope (magnification × 40)
Eur J Nucl Med Mol Imaging
may also put patients at risk for new infections. Nonetheless,
the risks of causing new infections though arthroscopy, main-
ly through the transfer of skin flora to the joint cavity, are
estimated as very low (< 1%) [22]. Thirdly, the results of this
study show that vanco-800CW is capable of detecting a rep-
resentative panel of bacterial species in vitro. However, in the
presented post-mortem arthroplasty experiments only a
S. epidermidis strain was used. The reliability of this tool for
the detection of other bacterial species is therefore yet to be
established, and such experiments might include bacteria in-
capable of biofilm formation as negative controls. Finally, our
in vitro method of biofilm formation on the prosthesis, in a
laboratory setting with excess nutrients and controlled envi-
ronmental conditions, does probably not fully resemble
biofilms as they appear in vivo in patients. Nonetheless, we
demonstrated the presence of EPS in the in vitro grown
biofilms with Congo Red, which is proof of their authenticity
[23]. However, biofilms grown in a laboratory setting with
excess nutrients and controlled environmental conditions will
be different from the ones that develop in patients. In addition,
the arthroscopy experiments were conducted in a post-mortem
setting, which undoubtedly presents differences with the actu-
al in vivo situation. It will therefore be important to extend our
proof-of-principle studies to in vivo arthroscopy in PJI animal
models [24] and to examine whether vanco-800CW is capable
of detecting real patient-derived biofilms (ex vivo) on infected
biomaterials.
Conclusion
This proof-of-principle study shows for a human prosthet-
ic post-mortem infection model that arthroscopic detec-
tion and imaging of PJIs caused by GP bacteria is feasible
with vanco-800CW. Its ability to directly and rapidly de-
tect bacterial biofilms makes it stand out in comparison to
other currently applied diagnostic approaches in clinical
microbiology. This view is underpinned by the affinity of
vanco-800CW for biofilms of a representative panel of
clinically relevant bacterial species associated with bio-
material infections. We therefore believe that the here
presented novel diagnostic modality holds great promise
for clinical implementation with the exciting perspective
of accurate and fast in situ diagnosis of PJIs.
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